Pediatrix Shows No Red Flags in Latest Risk Scan

A spotless alert profile underscores operational stability

MD Pediatrix Medical Group, Inc.

In this report

01

Profitability & Margins

Gross, operating, net, EBITDA margin trends and alerts

→

02

Leverage & Solvency

Debt-to-equity, interest coverage, net debt/EBITDA

→

03

Cash Flow & Liquidity

Operating/free cash flow, current/quick/cash ratios

→

04

Earnings Quality

Income quality, accruals, SBC, capital intensity

→

05

Risk Summary

Alert dashboard, watchlist, investment implications

→

Profitability & Margin Erosion

Pediatrix Medical Group, Inc. (MD) — Margin Risk

Pediatrix Medical Group exhibits a solid profitability profile across all three margin metrics. Gross margin sits at 24.7%, modestly below its 10‑year average of 26.8% but showing a year‑over‑year improvement of 2.1 percentage points, indicating that cost efficiencies or pricing power are beginning to offset historical pressure. Operating margin is comfortably above the decade mean at 12.1% and resides in the 66th percentile, with a striking 15.5% YoY increase driven by better expense control. The most notable strength is the net margin of 8.6%, which not only surpasses the 10‑year average of –7.3% but also ranks in the 96th percentile, reflecting strong bottom‑line conversion and a resilient earnings base.

Gross margin remains below its 10‑year average, exposing the business to cost inflation risk if improvements stall.
Sustaining the rapid YoY gains in operating and net margins may be challenging without continued operational efficiencies.

Net margin at 8.6% is in the 96th percentile of its 10‑year range, indicating exceptional bottom‑line performance.
Operating margin improved by 15.5% YoY, reflecting strong expense discipline.

MD clear

The company’s margin trajectory is broadly positive, with operating and net margins improving at rates that outpace historical averages. Gross margin remains the weakest link, trailing its long‑term mean, yet the upward trend suggests the erosion is not structural but rather a short‑term pricing or cost variance that management appears to be correcting. The stability of operating margin combined with accelerating net profitability points to effective overhead management and favorable revenue mix.

Profitability & Margin Erosion

Pediatrix Medical Group, Inc. (MD) — Margin Trends

Leverage & Solvency

Pediatrix Medical Group, Inc. (MD) — Leverage Risk

Pediatrix Medical Group exhibits a relatively conservative capital structure compared with its historical norms. The current debt-to-equity ratio of 0.76x sits well below the ten‑year average of 0.95x and falls in the 13th percentile, indicating that equity financing dominates its balance sheet. Net debt to EBITDA is also modest at 1.0x, far under the decade’s mean of 3.5x and comfortably within typical safety thresholds for healthcare services firms. Together, these metrics suggest ample capacity to service existing obligations and absorb short‑term shocks.

Potential upward pressure on net‑debt/EBITDA if EBITDA growth slows while debt levels rise modestly
Exposure to regulatory or reimbursement changes that could affect cash flow and leverage ratios

Debt-to-equity ratio remains well below the 10‑year average, providing a solid equity cushion
Net‑debt/EBITDA at 1.0x signals ample capacity for future investment or strategic borrowing without breaching safety thresholds

MD clear

The company’s leverage profile remains stable, with debt-to-equity unchanged year‑over‑year and a slight 16.3% increase in net‑debt/EBITDA that still leaves the ratio at a low 1.0x. Both ratios are well beneath conventional red‑flag levels—generally 2.0x for debt‑to‑equity and 3.0x for net‑debt/EBITDA in this sector—indicating strong debt sustainability. No interest coverage data were provided, but the low leverage implies that any reasonable earnings stream would comfortably cover interest expense.

Cash Flow & Liquidity

Pediatrix Medical Group, Inc. (MD) — Cash Flow Risk

Pediatrix Medical Group demonstrates robust cash generation, with both operating cash flow (OCF) and free cash flow (FCF) rising year‑over‑year by $64.5 million and $68.1 million respectively. The OCF of $0.3 billion matches its 10‑year average, while FCF now exceeds the historical mean ($0.2 billion), indicating that the business is not only covering its operating expenses but also generating surplus cash after capital expenditures. Short‑term liquidity is solid: the current and quick ratios sit at 1.66×, modestly above the 10‑year averages of 1.62×, and the cash ratio has improved to 0.82× from a historical 0.52×, reflecting ample liquid assets to meet immediate obligations. Overall, cash flow quality is high and liquidity metrics are comfortably above typical safety thresholds.

Potential slowdown in operating cash conversion if revenue growth decelerates
Capital intensity spikes could pressure free cash flow despite current surplus
Liquidity buffers, while improving, remain below a 1.0× cash ratio, leaving limited room for sudden cash outflows

Operating and free cash flows both improved year‑over‑year, indicating strong cash generation momentum
Current, quick, and cash ratios all trending upward, enhancing short‑term financial flexibility

MD clear

Operating cash flow of $300 million aligns with the company’s decade‑long average, but the YoY increase of $64.5 million signals accelerating earnings conversion into cash. Free cash flow, now also at $300 million, surpasses its 10‑year mean by $100 million and shows a $68.1 million uplift, confirming that capital spending is not eroding cash generation. The current and quick ratios of 1.66× each exceed the conventional 1.0× safety benchmark, while the cash ratio of 0.82×—well above the historical 0.52×—provides an additional cushion for short‑term liabilities.

Earnings Quality

Pediatrix Medical Group, Inc. (MD) — Earnings Quality Risk

The earnings quality profile for Pediatrics Medical Group, Inc. shows a strong alignment between reported net income and cash generation. The operating cash flow to net income ratio of 1.64x is well above the 10‑year average of 0.46x and indicates that each dollar of earnings is supported by $1.64 of cash, suggesting robust earnings persistence. Accruals are modestly negative at -4.7%, an improvement from a historical average of -10.1% and implying limited reliance on non‑cash accounting adjustments.

Potential future increase in accruals if revenue growth accelerates faster than cash collection
Rising capital expenditures could compress free cash flow if expansion plans intensify

Operating cash flow exceeds net income by 64%, providing a strong cushion for earnings sustainability
Accrual ratio is improving and remains negative, indicating conservative accounting
Stock‑based compensation burden is negligible, preserving earnings quality
CapEx intensity is low relative to cash generation, supporting free cash flow expansion

MD clear

Pediatrics Medical Group demonstrates high earnings quality, with cash flow comfortably covering reported profit and a stable accrual profile that does not signal aggressive revenue recognition. Stock‑based compensation is effectively zero as a share of revenue, removing a common source of dilution and expense volatility. Capital expenditures are modest at 7% of operating cash flow, well under the decade average of 15%, indicating low capital intensity and ample free cash generation for debt service or shareholder returns.

Risk Summary & Watchlist

Pediatrix Medical Group, Inc. (MD) — Risk Dashboard

The risk assessment across the reviewed universe reveals an overall clean risk profile, with Pediatrix Medical Group, Inc. (MD) showing zero alerts in any monitored category. The absence of critical or warning signals suggests that the company currently operates within acceptable thresholds for margins, leverage, cash flow, and quality metrics. Consequently, there are no immediate compounding risks such as margin erosion paired with rising debt that would elevate its risk posture. While the lack of alerts denotes stability, continued vigilance is advisable to ensure emerging issues are captured promptly.

Risk Rankings

MD clear

No identified risks; all key financial and operational metrics within safe bounds.

Key Concern: None – the company exhibits a clean risk profile.

Watchlist

Monitor Pediatrix Medical Group's quarterly earnings releases for any emerging margin or leverage trends.
Track industry regulatory developments that could impact pediatric healthcare reimbursement rates.

INVESTMENT IMPLICATIONS

Given the clean risk slate, investors can consider Pediatrix Medical Group as a lower‑risk component within a diversified portfolio, focusing on its growth prospects and cash flow generation rather than defensive positioning. However, the absence of red flags does not guarantee future performance; investors should remain attentive to sector‑specific dynamics such as changes in healthcare policy, payer mix shifts, and competitive pressures that could alter risk characteristics. In the near term (6‑12 months), the primary investment consideration is operational execution—maintaining stable margins and prudent capital structure. Should any adverse developments arise, the company’s current resilience provides a buffer, but proactive monitoring will be essential to preserve its favorable risk standing.

Key Takeaways

1. Pediatrix Medical Group registers zero alerts across all risk categories, indicating a clear risk profile.
2. No cross‑company risk themes are present due to the singular focus of this analysis.
3. The primary watch item is ongoing monitoring of margins and leverage in future reporting periods.
4. Investors may view the company as lower risk but should stay alert to sector‑specific regulatory changes.

MD

Related Reports

Explore more at Finexus Reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.